Often-passed plant in Colorado has a new owner, who's already operating nearby
A manufacturing facility in Longmont, CO will have new occupants soon.
AGC Biologics, a CDMO with headquarters in Denmark, signed a purchase agreement to take over a cell and gene therapy site that’s currently owned by Novartis.
Novartis leased the site from AstraZeneca just a little over a year ago, with the hopes of ramping up manufacturing for Zolgensma, the controversial gene therapy for children younger than 2 years old with atrophy. At the end of March, a Novartis spokesperson said that the company would leave Longmont by July “at the latest,” which would leave 400 employees without a job. It was the second Colorado plant the company had walked away from in the last four years, as it shuttered Broomfield operations and cut 450 jobs over two years due to declining sales.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 113,300+ biopharma pros reading Endpoints daily — and it's free.